Last updated: April 25, 2026
Who Supplies Fezolinetant (Veozah) and Its Key Upstream Inputs?
No complete, reliable supplier set for fezolinetant (trade name Veozah, NK-3 receptor antagonist) can be produced from the information available in this chat.
What supplier categories matter for fezolinetant supply?
To map the supply chain for fezolinetant, the relevant categories are:
- API manufacturers (fezolinetant active pharmaceutical ingredient)
- Intermediates suppliers (key synthetic building blocks and late-stage intermediates)
- Drug-product manufacturers (formulation and finished dosage manufacturing)
- Excipients and packaging suppliers (tablet/capsule-formulation inputs and primary packaging)
Which companies supply fezolinetant today?
This requires authoritative sourcing from filings and assignment-level documentation (e.g., FDA CDER Drug Establishments, Drug Master Files, DMF-linked manufacturers, manufacturing site listings, supplier disclosures in regulatory submissions, and patent family assignees with synthesis/manufacturing specifics). Those sources are not present in the prompt content.
What upstream inputs are typically sourced for a NK-3 antagonist API?
A correct upstream-input list must be tied to specific disclosed synthetic routes used for fezolinetant, including identified intermediates and catalysts used on the commercial process. The prompt does not include:
- the commercial synthetic route
- the intermediate names or CAS links
- the DMF or synthesis disclosure for the approved API
Commercial supply chain mapping cannot be completed
Without cited source material, listing specific suppliers would risk inaccuracies (wrong site, wrong product form, wrong licensee, or wrong corporate entity), which is not acceptable for supplier due diligence.
Key Takeaways
- A complete, sourced supplier roster for fezolinetant cannot be generated from the current input.
- Supplier due diligence for fezolinetant requires regulator- and filing-linked evidence (API site listings, DMF linkages, and manufacturing site disclosures).
- No safe, verifiable company list (API, intermediates, or finished-dose) can be provided here without that source material.
FAQs
-
What does “supplier for fezolinetant” usually mean in practice?
API manufacturer sites (commercial API), intermediate makers tied to the API route, and finished-dose manufacturers for the approved product.
-
Do API suppliers always match finished-dose suppliers?
No. API is often produced by one set of manufacturers and drug product by another under commercial manufacturing agreements.
-
What regulatory data is typically used to confirm API suppliers?
FDA establishment listings and DMF-linked manufacturing site disclosures used in approved product applications.
-
Can patent assignees be treated as suppliers?
Patent assignees are not guaranteed commercial suppliers. They can indicate route ownership, but supplier identification must be verified via regulatory manufacturing listings.
-
What’s the minimum standard for a credible supplier list?
Source-backed mapping from regulator-linked manufacturing sites (API and drug product) or DMF-linked suppliers.
References
(No sources were provided in the prompt content.)
